DUBLIN–(BUSINESS WIRE)–The “Psoriasis
Drugs Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The psoriasis drugs market is expected to register a CAGR of 9.3% during
the forecast period
The primary factors that are responsible for the growth of this market
include the increasing disease burden and demand for psoriasis medicines
in emerging economies, the increasing use of combination therapies, and
the increase in psoriasis research and pipeline drugs.
Among all these factors, one of the factors expected to have a major
impact on the market growth is the increasing use of combination
therapies. Research is continuing on this combination therapies
approach. However, studies conducted suggest that it often eases
psoriasis symptoms more effectively than either treatment by themselves.
Biologics usually take a while to work. Combining a biologic with a
faster-acting systemic drug, such as cyclosporine, is usually much more
effective and safer. With faster, longer-lasting results and fewer side
effects, requiring lower doses, many doctors are prescribing combination
therapies, which is, in turn, expected to drive the psoriasis drugs
market. However, factors such as side effects of existing medications
may have a negative impact on market growth.
Scope of the Report
Psoriasis is a genetic condition which may not be present at birth. This
genetic condition may also be triggered by certain environmental and
genetic factors. Factors such as the changing lifestyles of people are
leading to increased alcohol consumption and smoking, unhealthy diets,
and sedentary living, are making people more prone to this condition.
Key Market Trends
Interleukin Inhibitors is Expected to Grow with High CAGR in the
Forecasted Period
Interleukin inhibitors may witness the fastest growth during the
forecast period, and the factors aiding these Interleukin inhibitors are
their improved safety and efficacy when compared to other psoriasis
drugs, and their increased adoption among end users. Drugs like
Secukinumab, and Ustekinumab, among others, are aiding market growth as
the usage of drugs is increasing each year. Another benefit of the
IL-mode of therapy is for the patients who are intolerant or
contraindicated to TNF- inhibitor therapy.
North America Dominates the Market and is Expected to do so in the
Forecast Period
North America currently dominates the market for psoriasis drugs, and it
is expected to continue having a stronghold for a few more years. In
North America, the United States holds the largest market share. This
can be majorly attributed to the increasing prevalence of psoriasis, the
presence of favorable government initiatives, the presence of developed
healthcare infrastructure, high adoption of therapeutics, and the
presence of key drug manufacturers. All these factors are expected to
propel the market in the United States.
Competitive Landscape
The psoriasis drugs market is moderately competitive and consists of
several major players. In terms of market share, few of the major
players currently dominate the market. The rising number of patients is
attracting a few other players to enter the market, and a few smaller
players are also expected to enter the market in the future, who may
hold a substantial share. Companies are focused on business expansion in
developing regions or emerging markets, such as India, China, and South
Korea, by adopting strategies including alliances and acquisitions for
development of novel products.
Some of the major players of the market are Eli Lilly and Company,
Pfizer Inc., Johnson and Johnson (Janssen Global Services LLC), Novartis
AG, and Amgen Inc., among others.
Key Topics Covered:
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Disease Burden and Demand for Psoriasis Medicines in
Emerging Economies
4.2.2 Increasing Use of Combination Therapies
4.2.3 Increase in Psoriasis Research and Pipeline Drugs
4.3 Market Restraints
4.3.1 Adverse Side Effects of Existing Medications
4.3.2 High Cost of Psoriasis Treatments
4.3.3 Extensive Drug Development and Approval Process
4.4 Porter’s Five Force Analysis
5 MARKET SEGMENTATION
5.1 By Type of Treatment
5.1.1 Biologic Drugs
5.1.2 Small Molecule Systemic Drugs
5.1.3 Tropical Therapies
5.2 By Mechanism of Action
5.2.1 TNF Alpha Inhibitors
5.2.1.1 Etanercept
5.2.1.2 Certolizumab Pegol
5.2.1.3 Adalimumab
5.2.1.4 Infiximab
5.2.1.5 Golimumab
5.2.2 PDE4 Inhibitors
5.2.2.1 Apremilast
5.2.3 Interleukin Inhibitors
5.2.3.1 Secukinumab
5.2.3.2 Ustekinumab
5.2.3.3 Other Interleukin Inhibitors
5.2.4 Other Mechanisms of Action
5.3 By Route of Administration
5.3.1 Oral
5.3.2 Parenteral
5.3.3 Topical
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Pfizer Inc.
6.1.3 Johnson and Johnson (Janssen Biotech Inc.)
6.1.4 Celgene Corporation
6.1.5 Takeda Pharmaceutical Company Limited
6.1.6 Stiefel Laboratories Inc.
6.1.7 Novartis AG
6.1.8 Amgen Inc.
6.1.9 Biogen Idec
6.1.10 AbbVie Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/t67po6
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Psoriasis
Drugs